Functional disturbances ofthe immune system have been detected more often among persons affected by epilepsy than in the general population. In the February-July period of 2007 a specific questionnaire on the relationship between epilepsy and immunological response was sent to 27 specialized Centres for Epilepsy in nine Italian regions. 15,388 epileptic patients attended twenty-seven Centers during this six-month period. 3.3% (n=502) of these patients suffered an immune disease. This is the first national survey on the relationship between epilepsy and immunological response in current clinical practice.
The relationship between the immune system and epilepsy has been studied since the late 1970's. Observational and experimental data report immune alterations in subjects affected by epilepsy and/or favourable responses to the treatment with immunomodulating drugs (1) (2) (3) Clinical and experimental evidence also showed that immune mediated and inflammatory mechanisms explain the pathogenesis of a certain number of epilepsies (4) (5) . In particular, the relationship between brain inflammation and seizures has a consistent clinical relevance in patients with drug resistant epilepsy (6) (7) . The following three clinical and experimental conditions are particularly interesting: infantile epileptic syndromes (immune-mediated epilepsy prototype is the Rasmussen encephalitis, but anti-GluR3 antibodies are not only related to the Rasmussen encephalitis and may be involved in several other forms ofepilepsy and other pathologies) (8) (9) ; epilepsy associated to autoimmune diseases (the relationship between epilepsy and autoimmune diseases has been observed in numerous clinical conditions and, in addition, since an epileptic seizure can be an early symptom of autoimmune diseases a delay in diagnosis may induce a wrong therapeutic approach) (10-11); a correct approach to epilepsy and immune parameters (a study on a large epileptic population confirmed how an IgA deficiency could be more frequent when compared with healthy subjects and how the epilepsy could be a selective symptom of immune deficiency; in addition it has been shown that IgG2 deficit in 25% of 368 untreatable epilepsy patients and proinflammatory cytokines increase after an epileptic crisis and evidence exists confirming that cytokines may induce an epileptic crisis) (12) (13) (14) .
Since in adult patients drug-resistant epilepsy (about the 30% of the cases, half of which cryptogenic) requires the use of more than one molecule increasing the probability of drugs resistance in accordance with Billiau (15) , we underline some critical points: I] the presence of immune alterations in a consistent fraction of epileptic subjects; 2] epileptic seizures as clinical expressions of autoimmune diseases;
3] the therapeutic response in some forins of epilepsy after immunomodulating drugs.
Overall, evidence exists that the pathogenesis of some forms of epilepsy can be immune-mediated, that autoantibodies and cell immunity playa critical role in neuronal excitability, that several autoimmune diseases show neurological symptoms and epileptic seizures and that therapeutic approach is not well defined.
Since an immunological approach is not routinely adopted in diagnostic procedure of epilepsy, a preliminary national recognition has been performed to identify the critical role of immune response in some kinds of epilepsy. In the February-July 2007 period, a specific questionnaire on the relationship between epilepsy and immunological response was sent to 27 specialized Centres for Epilepsy in nine Italian regions (Lazio, Sicilia, Campania, Puglia, Marche, Basilicata, Lombardia, Toscana, Piemonte). The questionnaire included the following: number of epileptic patients enrolled in the previous six months, number of epileptic patients with immune diseases, which diseases of the immune system have been associated with epilepsy, how many epileptic patients had had immunological laboratory testing and how many patients had shown alterations of immune parameters. Neurologists were asked with three basic questions: I] "do you consider the relationship between epilepsy and immunology in your current clinical practice?"; 2] "do you modify your therapeutic approach to epilepsy if immune alterations are observed?" 3] "If yes, how?". 15,388 epileptic patients attended Centers over a six-month period; 20.5% for a first visit and 79.5% for control visits. 3.3% (n=502) of these patients suffered an immune disease. The immune diseases more frequently reported were: systemic lupus erythematosus (40%), vasculitis (28%), autoimmune thyroiditis (28%), multiple sclerosis (20%), Rasmussen encephalitis (16%), acute dissimenated encephalo myelitis (ADEM) (16%), coeliac disease (16%), type I mellitus diabetes (16%). Immune laboratory tests were carried out on 1186 epileptic patients (7.7%). One ore more alterations of immunological parameters were found in 77.2% of this group (916/1186).
Twenty neurologists (71.4%) considered the relationship between epilepsy and immune response and the same percentage of epileptic specialists reported that the presence of immune alterations may influence their therapeutic approach to epilepsy. Proposed therapeutical variations consisted in the use of steroids and immune globulin (20%), change of antiepileptic drugs (20%), prescribing other laboratory exams and a more restricted followup (8%), introduction of specific therapy for the immune disorders (8%), an increasing attention versus drug interactions (4%), and use of immune suppressors (4%).
Our data show that although 71.4% of epileptic specialistsconsideredrelevant the relationshipbetween epilepsy and immune response, only 7.7% of epileptic patients who attended 27 Centres for Epilepsy during the six month study period had laboratory tests carried out to study immunologicalparameters.
We consider the implementation of an integrate approach between research aspects and current clinical practice in the assessment of the relationship regarding epilepsy and immunological response as a serious problem. From a public health point of view, this issue may be really useful for the appropriate pharmacological treatment of epileptic patients.
In addition, since neurologists did not substantially modify their clinical and therapeutic approach when immune alterations were reported in their patients, a more extensive project among a larger number of Italian Centres for epilepsy has been planned to evaluate the diagnostic approach. Such project would be aimed at identifying the immune causes of the epileptic seizures, to collect data on autoimmune systemic diseases showing early epileptic symptoms, to select patients with "cryptogenic" epilepsy and alterations of humoral and cell-immune parameters (data in progress).
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